Summary
MMB-2201, known by various aliases such as 5F-MMB-PICA, 5F-AMB-PICA, and I-AMB, is a potent synthetic cannabinoid founded on the indole-3-carboxamide structure. This compound has gained notoriety for its presence in the designer drug market and its use as an active component in synthetic cannabis blends. While it initially emerged in Russia and Belarus in January 2014, MMB-2201 has entered numerous other countries. Notably, in the United States, the Drug Enforcement Administration (DEA) first detected MMB-2201 in drug seizures in 2018.
MMB-2201 can be regarded as the indole core analogue of 5F-AMB. Compounds within the category of synthetic cannabinoids featuring an indole-3-carboxamide or indazole-3-carboxamide core accompanied by an N-1-methoxycarbonyl group and linked to isopropyl or tert-butyl substituents have been associated with heightened risks compared to earlier synthetic cannabinoids. These substances have been implicated in numerous fatalities in regions such as Russia, Japan, Europe, and the United States.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 1616253-26-9 |
|---|---|
| PubChem CID | 119058037 |
| ChemSpider | 30922499 |
| UNII | 744M0WHE80 |
| Chemical and physical data | |
| Formula | C20H27FN2O3 |
| Molar mass | 362.445 g·mol−1 |
Legality
MMB-2201 is illegal in Russia, Belarus and Sweden.
FAQ
1. What is MMB-2201?
- MMB-2201, also known as 5F-MMB-PICA, 5F-AMB-PICA, and I-AMB, is a potent synthetic cannabinoid in the indole-3-carboxamide class.
2. How has MMB-2201 been used in the designer drug market?
- MMB-2201 has been sold as a designer drug and has been incorporated as an active ingredient in synthetic cannabis blends, often referred to as “spice” or “K2.”
3. When was MMB-2201 first reported, and in which countries has it been sold?
- MMB-2201 was initially reported in Russia and Belarus in January 2014. Since then, it has been distributed and sold in several other countries.
4. When did the Drug Enforcement Administration (DEA) identify MMB-2201 in the United States?
- MMB-2201 was first detected in DEA drug seizures in the United States in 2018.
5. How does MMB-2201 compare to other synthetic cannabinoids in terms of safety and health risks?
- Synthetic cannabinoids with an indole-3-carboxamide or indazole-3-carboxamide core and an N-1-methoxycarbonyl group, accompanied by isopropyl or tert-butyl substituents, have been associated with higher risks compared to earlier synthetic cannabinoids. They have been linked to several fatalities in various regions, including Russia, Japan, Europe, and the United States.
6. What is the legal status of MMB-2201 in different countries?
- The legal status of MMB-2201 can vary by country and jurisdiction. It is crucial to be aware of the specific laws and regulations in your area regarding the use, possession, and distribution of this substance.
7. Can MMB-2201 be detected in drug tests?
- The ability to detect MMB-2201 in drug tests may depend on the specific tests used and their sensitivity to this substance.
8. Where can I find more information about MMB-2201 and its effects?
- For comprehensive information on MMB-2201, including its chemical properties, legal status, potential health risks, and responsible use guidelines, consult reputable sources such as government health agencies, medical professionals, and substance abuse organizations.
References
- In a comprehensive study conducted in July 2016 by Samuel D. Banister and colleagues, the pharmacology of various synthetic cannabinoids, including 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues, was explored. This research, published in ACS Chemical Neuroscience (Volume 7, Issue 9), provides valuable insights into the properties of these substances. You can access the study through doi:10.1021/acschemneuro.6b00137, with the PMID 27421060.
- For information on MMB-2201, you can refer to Cayman Chemical. Details regarding MMB-2201 are accessible and were retrieved on July 16, 2015.
- Shan Yin’s work in 2019, titled “Adolescents and Drug Abuse: 21st Century Synthetic Substances,” published in Clinical Pediatric Emergency Medicine (Volume 20, Issue 1), delves into the challenges of drug abuse among adolescents in the context of contemporary synthetic substances. The study can be found via doi:10.1016/j.cpem.2019.03.003, and it is identified with S2CID 88290992.
- In a July 2014 research article by V. A. Shevyrin, Yu. Yu. Morzherin, V. P. Melkozerov, and A. S. Nevero, a new synthetic cannabinoid known as “Methyl 2-{[1-(5-Fluoro-Pentyl)-3-Methyl-1H -Indol-3-Ylcarbonyl]-Amino}Butyrate” is explored as a designer drug. This research is published in Chemistry of Heterocyclic Compounds (Volume 50, Issue 4) and can be accessed through doi:10.1007/s10593-014-1511-6, with S2CID 97489753.
- Another study by Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, and Lebedev AT in April 2015 provides information on the identification and analytical characteristics of synthetic cannabinoids featuring an indazole-3-carboxamide structure with an N-1-methoxycarbonylalkyl group. This study was published in Analytical and Bioanalytical Chemistry (Volume 407, Issue 21) and can be accessed via doi:10.1007/s00216-015-8612-7. The PMID is 25893797, and it is identified with S2CID 31838655.
- For additional insights into the classification of cannabinoids as potentially hazardous substances, the “Cannabinoider föreslås bli klassade som hälsofarlig vara” article by Folkhälsomyndigheten, retrieved on June 29, 2015, offers relevant information.